FDA grants Breakthrough Therapy Designation for the company's treatment of Sanfilippo Syndrome, a rare neurodegenerative disorder.
The energy giant will use the proceeds to accelerate debt reduction and focus on its core oil and gas business.
The transaction creates the ninth-largest U.S. bank, fueling a new wave of consolidation in the regional banking sector.
FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
The acquisition creates the ninth-largest U.S. bank and signals accelerating consolidation within the regional banking sector.
FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.